Tranexamic Acid for Blood Cancers
(MYELO-CAN:TXA Trial)
Trial Summary
What is the purpose of this trial?
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and/or severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.
Eligibility Criteria
Adults over 18 with myelodysplastic syndromes or acute myeloid leukemia, who are receiving less-intensive chemotherapy and have severe thrombocytopenia (very low platelet counts). It's not for those outside these criteria.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either tranexamic acid or placebo to evaluate the effectiveness and safety in preventing bleeding in MDS and AML patients
Follow-up
Participants are monitored for safety and effectiveness after treatment, including incidence of visual disturbances and thromboembolism
Treatment Details
Interventions
- Tranexamic Acid
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Manitoba
Lead Sponsor